CliveSZentMD
Hematology • Rochester, NYHematologic Oncology
Professor, Wilmot Cancer Institute, University of Rochester
Dr. Zent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
601 Elmwood Avenue
Box 704
Rochester, NY 14642Phone+1 585-273-3258- Is this information wrong?
Education & Training
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1996 - 1997
University of ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Cape TownMMed, 1987 - 1990
University of the WitwatersrandClass of 1983
Certifications & Licensure
NY State Medical License 2013 - 2025
MN State Medical License 2003 - 2014
AR State Medical License 1996 - 2003
IL State Medical License 1993 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated Start of enrollment: 2004 Jul 01
- Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia Start of enrollment: 2004 Dec 01
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.Hill, B., Ma, S., Zent, C., Baran, A., Wallace, D., Advani, A., Winter, A., Winter, J., Gordan, L., Karmali, R., Liesveld, J., Mulford, D., Rowland, C., Bui, A., Sport...> ;Blood Advances. 2024 Jan 23
- 3 citationsAntibody-mediated phagocytosis in cancer immunotherapy.Carly M Van Wagoner, Fátima Rivera-Escalera, Nydia C Jaimes-Delgadillo, Charles C Chu, Clive S Zent, Michael R Elliott> ;Immunological Reviews. 2023 Oct 1
- 2 citationsLong-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymph...Michael T Brady, Nathan Laniewski, Myla Strawderman, Charles C Chu, Preshetha Kanagaiah, Mark Y Sangster, David J Topham, Jonathan W Friedberg, Clive S Zent> ;American Journal of Hematology. 2023 Oct 1
- Join now to see all
Journal Articles
- CD20 and CD37 Antibodies Synergize to Activate Complement by Fc-Mediated ClusteringRonald P Taylor, Clive S Zent, Haematologica
Abstracts/Posters
- Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug ChoiceClive S Zent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Clive S Zent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Wilmot Cancer Institute Secures $13.6 Million in GrantsAugust 8th, 2022- Shingles Vaccine Shows Promise in Lymphoma PatientsNovember 10th, 2020
Professional Memberships
- Member
Hospital Affiliations
Strong Memorial Hospital of the University of RochesterRochester, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
